Verrica Pharmaceuticals Inc (FRA:1NE)
€ 0.593 -0.0645 (-9.81%) Market Cap: 59.47 Mil Enterprise Value: 82.64 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 33/100

Verrica Pharmaceuticals Inc at RBC Capital Markets Global Healthcare Conference Transcript

May 17, 2023 / 12:30PM GMT
Release Date Price: €5.5
Greg Renza
RBC Capital Markets - Analyst

-- to the 2023 RBC Global Healthcare Conference. My name is Greg Renza, one of the senior biotechnology equity research analysts here at RBC. And we're pleased to have Verrica with us today. And joining us and representing the company is the President and CEO, Ted White.

Ted White
Verrica Pharmaceuticals Inc. - President & CEO

[Hi], it's good to be with you.

Greg Renza
RBC Capital Markets - Analyst

Ted, it's good to be with you, and a lot going on the Verrica front, especially with PDUFA coming up, a potential game changer for patients and families.

Questions & Answers

Greg Renza
RBC Capital Markets - Analyst

But maybe to just begin, Ted, and just taking a step back for those who aren't familiar or as familiar with the Verrica story, just give us a brief intro to the company and your lead asset, YCANTH.

Ted White
Verrica Pharmaceuticals Inc. - President & CEO

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot